Skip to NavigationSkip to content

FDA approves Teva's Ajovy autoinjector for treatment of migraine

Published on 29/01/20 at 10:29am

Israeli pharma firm Teva has revealed that the FDA has chosen to award approval to its autoinjector device for the delivery of its Ajovy (fremanezumab-vfrm) solution, used to treat patients with migraine.

The approval means that US patients will now have access to a delivery option which lets them self-administer the drug. The device is expected to be made available “in the coming months”.

“The approval of the Ajovy autoinjector is another important step forward for Teva and the migraine community,” remarked Brendan O’Grady, Executive Vice President, North America Commercial at Teva. “Ajovy is the only FDA-approved anti-CGRP that offers the flexibility of quarterly (675 mg) or monthly (225 mg) dosing options, and we are pleased that patients and their healthcare providers will be able to decide if an autoinjector is the right administration option for their needs.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches